Приказ основних података о документу
Influence of Cyp2c19∗2 Gene Variant on Therapeutic Response during Clopidogrel Treatment in Patients with Carotid Artery Stenosis
dc.creator | Backović, Dragana | |
dc.creator | Ignjatović, Svetlana | |
dc.creator | Rakicević, Ljiljana | |
dc.creator | Kusić-Tisma, Jelena | |
dc.creator | Radojković, Dragica | |
dc.creator | Čalija, Branko | |
dc.creator | Strugarević, Evgenija | |
dc.creator | Radak, Đorđe | |
dc.creator | Kovac, Mirjana | |
dc.date.accessioned | 2019-09-02T11:51:35Z | |
dc.date.available | 2019-09-02T11:51:35Z | |
dc.date.issued | 2016 | |
dc.identifier.issn | 1452-8258 | |
dc.identifier.uri | https://farfar.pharmacy.bg.ac.rs/handle/123456789/2573 | |
dc.description.abstract | Background: Despite the proven clinical effect of oral antiplatelet drugs, a considerable number of patients do not have an adequate response to clopidogrel. The aim of our study was to determine the influence of CYP2C19*2 loss-of-function variant allele on clopidogrel responsiveness in patients with carotid artery stenosis. Methods: One hundred and twelve patients with carotid artery stenosis undergoing endarterectomy were included in this one-year prospective study. All of them received clopidogrel (75 mg daily) for at least 30 days after the intervention. They were followed from the moment of hospital admission. CYP2C19*2 genotyping was performed by TaqMan Assay. The influence of CYP2C19*2 variant allele on clopidogrel platelet reactivity was determined using multiple-electrode aggregometry (MEA). Results: Genotyping results showed that 82 (73.2%) patients were homozygous for wild type, 29 (25.9%) were heterozygous for the CYP2C19*2 allele and 1 (0.9%) was CYP2C19*2 homozygous. After 24 hours, among those with the wild type 29.3% were clopidogrel responders, and in those with the CYP2C19*2 alleles 10%. In the wild type group, 74.4% were clopidogrel responders after 7 days of taking the drug; 82.9% after 30 days of clopidogrel introduction, respectively. In patients with the CYP2C19*2 alleles the number of responders increased up to 46.7% after 7 days; 53.3% after 30 days of taking the drug, respectively. The risk for being a low-responder is higher for the patients heterozygous for the CYP2C19*2 allele vs. wild type (OR 4.250, 95% CI 1.695-10.658, P lt 0.01). Conclusions: The CYP2C19*2 loss-of-function variant allele has significant influence on clopidogrel response in patients with carotid artery stenosis undergoing endarterectomy. | en |
dc.publisher | Društvo medicinskih biohemičara Srbije, Beograd i Versita | |
dc.relation | info:eu-repo/grantAgreement/MESTD/Basic Research (BR or ON)/173008/RS// | |
dc.rights | openAccess | |
dc.source | Journal of Medical Biochemistry | |
dc.title | Influence of Cyp2c19∗2 Gene Variant on Therapeutic Response during Clopidogrel Treatment in Patients with Carotid Artery Stenosis | en |
dc.type | article | |
dc.rights.license | ARR | |
dcterms.abstract | Стругаревић, Евгенија; Ракицевић, Љиљана; Кусић-Тисма, Јелена; Радојковић, Драгица; Радак, Ђорђе; Бацковић, Драгана; Ковац, Мирјана; Игњатовић, Светлана; Чалија, Бранко; | |
dc.citation.volume | 35 | |
dc.citation.issue | 1 | |
dc.citation.spage | 26 | |
dc.citation.epage | 33 | |
dc.citation.other | 35(1): 26-33 | |
dc.citation.rank | M23 | |
dc.identifier.wos | 000371751500004 | |
dc.identifier.doi | 10.1515/jomb-2015-0009 | |
dc.identifier.pmid | 28356861 | |
dc.identifier.scopus | 2-s2.0-84961360668 | |
dc.identifier.fulltext | https://farfar.pharmacy.bg.ac.rs//bitstream/id/1249/2571.pdf | |
dc.type.version | publishedVersion |